Your browser doesn't support javascript.
loading
Factors Associated with All-Cause 30-Day Mortality in Indonesian Inpatient COVID-19 Patients at Cipto Mangunkusumo National General Hospital.
Rinaldi, Ikhwan; Yulianti, Mira; Yunihastuti, Evy; Rajabto, Wulyo; Irawan, Cosphiadi; Sukrisman, Lugyanti; Rachman, Andhika; Mulansari, Nadia Ayu; Lubis, Anna Mira; Prasetyawaty, Findy; Cahyanur, Rahmat; Priantono, Dimas; Ahani, Ardhi Rahman; Muthalib, Abdul; Sudoyo, Aru; Atmakusuma, Tubagus Djumhana; Reksodiputro, Arry Harryanto; Djoerban, Zubairi; Tambunan, Karmel; Winston, Kevin; Shufiyani, Yuli Maulidiya; Wiyono, Lowilius; Pratama, Samuel; Edina, Brenda Cristie.
Afiliação
  • Rinaldi I; Hematology and Medical Oncology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Yulianti M; Respirology and Critical Care, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Yunihastuti E; Allergy and Immunology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Rajabto W; Hematology and Medical Oncology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Irawan C; Hematology and Medical Oncology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Sukrisman L; Hematology and Medical Oncology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Rachman A; Hematology and Medical Oncology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Mulansari NA; Hematology and Medical Oncology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Lubis AM; Hematology and Medical Oncology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Prasetyawaty F; Hematology and Medical Oncology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Cahyanur R; Hematology and Medical Oncology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Priantono D; Hematology and Medical Oncology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Ahani AR; Hematology and Medical Oncology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Muthalib A; Hematology and Medical Oncology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Sudoyo A; Hematology and Medical Oncology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Atmakusuma TD; Hematology and Medical Oncology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Reksodiputro AH; Hematology and Medical Oncology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Djoerban Z; Hematology and Medical Oncology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Tambunan K; Hematology and Medical Oncology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Winston K; Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Shufiyani YM; Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Wiyono L; Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Pratama S; Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
  • Edina BC; Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
J Clin Med ; 13(10)2024 May 20.
Article em En | MEDLINE | ID: mdl-38792539
ABSTRACT

Introduction:

Indonesia, as a developing country, has limited data on the factors associated with 30-day mortality in COVID-19 patients in Indonesia. As a matter of fact, study analyzing factors associated with 30-day mortality of COVID-19 infection in Indonesia has never been conducted. This study aims to fill this gap in the literature by conducting a large-scale analysis of factors associated with 30-day mortality in COVID-19 patients in Indonesia.

Method:

This study employed a single-center retrospective cohort observational design, and was conducted at Cipto Mangunkusumo National General Hospital between the years 2022 and 2023. Sampling was conducted using the consecutive sampling method. The study included patients aged 18 years and above who had been confirmed to have COVID-19 infection. Survival analysis was conducted using Kaplan-Meier and multivariate Cox regression analysis.

Result:

Our study included a total of 644 patients, with 120 patients (18.6%) expiring within 30 days. In the multivariate analysis using the backward Wald method, severe COVID-19 (HR 7.024; 95% CI 3.971-12.744; p value <0.0001), moderate COVID-19 infection (HR 1.660; 95% CI 1.048-2.629; p value 0.031), liver cirrhosis (HR 3.422; 95% CI 1.208-9.691; p value 0.021), female sex (HR 1.738; 95% CI 1.187-2.545; p value 0.004), old age (HR 2.139; 95% CI 1.279-3.577; p value 0.004), high leukocyte (HR 11.502; 95% CI 1.523-86.874; p value 0.018), high NLR (HR 1.720; 95% CI 1.049-2.819; p value 0.032), high CRP (HR 1.906; 95% CI 1.092-3.329; p value 0.023), high procalcitonin (HR 3.281; 95% CI 1.780-6.049; p value 0.001), and high creatinine (HR 1.863; 95% CI 1.240-2.800; p value 0.003) were associated with 30-day mortality from COVID-19 infection. Subgroup analysis excluding cancer patients showed that age, D-Dimer, CRP, and PCT were associated with 30-day mortality in COVID-19 patients, while steroid therapy is protective.

Conclusions:

This study finds that COVID-19 severity, liver cirrhosis, sex, age, leukocyte, NLR, CRP, creatinine, and procalcitonin were associated with COVID-19 mortality within 30 days. These findings underscore the multifactorial nature of COVID-19 infection mortality. It is important, therefore, that patients which exhibit these factors should be treated more aggressively to prevent mortality.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article